Koenig Sheldon L. sold $169K of ESPR
Koenig Sheldon L. (President and CEO) sold 53,588 shares of Esperion Therapeutics, Inc. (ESPR) at $3.16 ($0.17M total) on 2026-06-17.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO’s open-market sale details (shares, price, total value) and post-transaction holdings; it does not include any operational or financial update.
Market read
Traders may monitor for insider-selling trends, but this single, relatively small transaction is unlikely to drive a fundamental repricing.
What to watch
Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without context on total insider activity, the signal is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for Esperion Therapeutics, Inc. (ESPR).
Ticker impact
Esperion Therapeutics CEO Sheldon Koenig filed a Form 4 selling 53,588 shares for about $169K on 2026-06-17.
Likely minimal near-term price impact; any effect would be sentiment-driven and short-lived.
The filing is a standard insider transaction with no 10b5-1 plan and no accompanying fundamental catalyst (no guidance, trial, deal, or regulatory action).
Market effects
No direct sector read-through; this is company-specific insider dealing.
None indicated.
None indicated.
Counterpoint
Absence of a 10b5-1 plan could be interpreted by some traders as less “mechanical,” potentially increasing short-term scrutiny despite the modest dollar size.
Key entities
- issuerEsperion Therapeutics, Inc.
Subject of the Form 4 insider sale by CEO Sheldon Koenig.
- insiderKoenig Sheldon L.
President and CEO who sold 53,588 shares on 2026-06-17.